Inhibition of MCL-1 in breast cancer cells promotes cell death in vitro and in vivo

Clint Mitchell, Adly Yacoub, Hossein Hamed, Aditi Pandya Martin, M. Danielle Bareford, Patrick Eulitt, Chen Yang, Kenneth Nephew, Paul Dent

Research output: Contribution to journalArticle

56 Citations (Scopus)

Abstract

The present studies have examined approaches to suppress MCL-1 function in breast cancer cells, as a means to promote tumor cell death. Treatment of breast cancer cells with CDK inhibitors (flavopiridol; roscovitine) enhanced the lethality of the ERBB1 inhibitor lapatinib in a synergistic fashion. CDK inhibitors interacted with lapatinib to reduce MCL-1 expression and overexpression of MCL-1 or knock down of BAX and BAK suppressed drug combination lethality. Lapatinib-mediated inhibition of ERK1/2 and to a lesser extent AKT facilitated CDK inhibitor-induced suppression of MCL-1 levels. Treatment of cells with the BH3 domain/MCL-1 inhibitor obatoclax enhanced the lethality of lapatinib in a synergistic fashion. Knock out of MCL-1 and BCL-XL enhanced lapatinib toxicity to a similar extent as obatoclax and suppressed the ability of obatoclax to promote lapatinib lethality. Pre-treatment of cells with lapatinib or with obatoclax enhanced basal levels of BAX and BAK activity and further enhanced drug combination toxicity. In vivo tumor growth data in xenograft and syngeneic model systems confirmed our in vitro findings. Treatment of cells with CDK inhibitors enhanced the lethality of obatoclax in a synergistic fashion. Overexpression of MCL-1 or knock down of BAX and BAK suppressed the toxic interaction between CDK inhibitors and obatoclax. Obatoclax and lapatinib treatment or obatoclax and CDK inhibitor treatment or lapatinib and CDK inhibitor treatment radiosensitized breast cancer cells. Lapatinib and obatoclax interacted to suppress mammary tumor growth in vivo. Collectively our data demonstrate that manipulation of MCL-1 protein expression by CDK inhibition or inhibition of MCL-1 sequestering function by Obatoclax renders breast cancer cells more susceptible to BAX/BAK-dependent mitochondrial dysfunction and tumor cell death.

Original languageEnglish
Pages (from-to)903-917
Number of pages15
JournalCancer Biology and Therapy
Volume10
Issue number9
DOIs
StatePublished - Nov 1 2010

Fingerprint

Cell Death
Breast Neoplasms
alvocidib
Drug Combinations
obatoclax
lapatinib
In Vitro Techniques
Neoplasms
Poisons
Growth
Drug-Related Side Effects and Adverse Reactions
Heterografts
Proteins

Keywords

  • BAK
  • BCL-2 inhibitor
  • CDK inhibitor
  • Flavopiridol
  • Lapatinib
  • MCL-1
  • Obatoclax
  • Roscovitine
  • RTK inhibitor

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Molecular Medicine
  • Pharmacology

Cite this

Mitchell, C., Yacoub, A., Hamed, H., Martin, A. P., Bareford, M. D., Eulitt, P., ... Dent, P. (2010). Inhibition of MCL-1 in breast cancer cells promotes cell death in vitro and in vivo. Cancer Biology and Therapy, 10(9), 903-917. https://doi.org/10.4161/cbt.10.9.13273

Inhibition of MCL-1 in breast cancer cells promotes cell death in vitro and in vivo. / Mitchell, Clint; Yacoub, Adly; Hamed, Hossein; Martin, Aditi Pandya; Bareford, M. Danielle; Eulitt, Patrick; Yang, Chen; Nephew, Kenneth; Dent, Paul.

In: Cancer Biology and Therapy, Vol. 10, No. 9, 01.11.2010, p. 903-917.

Research output: Contribution to journalArticle

Mitchell, C, Yacoub, A, Hamed, H, Martin, AP, Bareford, MD, Eulitt, P, Yang, C, Nephew, K & Dent, P 2010, 'Inhibition of MCL-1 in breast cancer cells promotes cell death in vitro and in vivo', Cancer Biology and Therapy, vol. 10, no. 9, pp. 903-917. https://doi.org/10.4161/cbt.10.9.13273
Mitchell C, Yacoub A, Hamed H, Martin AP, Bareford MD, Eulitt P et al. Inhibition of MCL-1 in breast cancer cells promotes cell death in vitro and in vivo. Cancer Biology and Therapy. 2010 Nov 1;10(9):903-917. https://doi.org/10.4161/cbt.10.9.13273
Mitchell, Clint ; Yacoub, Adly ; Hamed, Hossein ; Martin, Aditi Pandya ; Bareford, M. Danielle ; Eulitt, Patrick ; Yang, Chen ; Nephew, Kenneth ; Dent, Paul. / Inhibition of MCL-1 in breast cancer cells promotes cell death in vitro and in vivo. In: Cancer Biology and Therapy. 2010 ; Vol. 10, No. 9. pp. 903-917.
@article{84bf98a2886849d682e102268ea352f0,
title = "Inhibition of MCL-1 in breast cancer cells promotes cell death in vitro and in vivo",
abstract = "The present studies have examined approaches to suppress MCL-1 function in breast cancer cells, as a means to promote tumor cell death. Treatment of breast cancer cells with CDK inhibitors (flavopiridol; roscovitine) enhanced the lethality of the ERBB1 inhibitor lapatinib in a synergistic fashion. CDK inhibitors interacted with lapatinib to reduce MCL-1 expression and overexpression of MCL-1 or knock down of BAX and BAK suppressed drug combination lethality. Lapatinib-mediated inhibition of ERK1/2 and to a lesser extent AKT facilitated CDK inhibitor-induced suppression of MCL-1 levels. Treatment of cells with the BH3 domain/MCL-1 inhibitor obatoclax enhanced the lethality of lapatinib in a synergistic fashion. Knock out of MCL-1 and BCL-XL enhanced lapatinib toxicity to a similar extent as obatoclax and suppressed the ability of obatoclax to promote lapatinib lethality. Pre-treatment of cells with lapatinib or with obatoclax enhanced basal levels of BAX and BAK activity and further enhanced drug combination toxicity. In vivo tumor growth data in xenograft and syngeneic model systems confirmed our in vitro findings. Treatment of cells with CDK inhibitors enhanced the lethality of obatoclax in a synergistic fashion. Overexpression of MCL-1 or knock down of BAX and BAK suppressed the toxic interaction between CDK inhibitors and obatoclax. Obatoclax and lapatinib treatment or obatoclax and CDK inhibitor treatment or lapatinib and CDK inhibitor treatment radiosensitized breast cancer cells. Lapatinib and obatoclax interacted to suppress mammary tumor growth in vivo. Collectively our data demonstrate that manipulation of MCL-1 protein expression by CDK inhibition or inhibition of MCL-1 sequestering function by Obatoclax renders breast cancer cells more susceptible to BAX/BAK-dependent mitochondrial dysfunction and tumor cell death.",
keywords = "BAK, BCL-2 inhibitor, CDK inhibitor, Flavopiridol, Lapatinib, MCL-1, Obatoclax, Roscovitine, RTK inhibitor",
author = "Clint Mitchell and Adly Yacoub and Hossein Hamed and Martin, {Aditi Pandya} and Bareford, {M. Danielle} and Patrick Eulitt and Chen Yang and Kenneth Nephew and Paul Dent",
year = "2010",
month = "11",
day = "1",
doi = "10.4161/cbt.10.9.13273",
language = "English",
volume = "10",
pages = "903--917",
journal = "Cancer Biology and Therapy",
issn = "1538-4047",
publisher = "Landes Bioscience",
number = "9",

}

TY - JOUR

T1 - Inhibition of MCL-1 in breast cancer cells promotes cell death in vitro and in vivo

AU - Mitchell, Clint

AU - Yacoub, Adly

AU - Hamed, Hossein

AU - Martin, Aditi Pandya

AU - Bareford, M. Danielle

AU - Eulitt, Patrick

AU - Yang, Chen

AU - Nephew, Kenneth

AU - Dent, Paul

PY - 2010/11/1

Y1 - 2010/11/1

N2 - The present studies have examined approaches to suppress MCL-1 function in breast cancer cells, as a means to promote tumor cell death. Treatment of breast cancer cells with CDK inhibitors (flavopiridol; roscovitine) enhanced the lethality of the ERBB1 inhibitor lapatinib in a synergistic fashion. CDK inhibitors interacted with lapatinib to reduce MCL-1 expression and overexpression of MCL-1 or knock down of BAX and BAK suppressed drug combination lethality. Lapatinib-mediated inhibition of ERK1/2 and to a lesser extent AKT facilitated CDK inhibitor-induced suppression of MCL-1 levels. Treatment of cells with the BH3 domain/MCL-1 inhibitor obatoclax enhanced the lethality of lapatinib in a synergistic fashion. Knock out of MCL-1 and BCL-XL enhanced lapatinib toxicity to a similar extent as obatoclax and suppressed the ability of obatoclax to promote lapatinib lethality. Pre-treatment of cells with lapatinib or with obatoclax enhanced basal levels of BAX and BAK activity and further enhanced drug combination toxicity. In vivo tumor growth data in xenograft and syngeneic model systems confirmed our in vitro findings. Treatment of cells with CDK inhibitors enhanced the lethality of obatoclax in a synergistic fashion. Overexpression of MCL-1 or knock down of BAX and BAK suppressed the toxic interaction between CDK inhibitors and obatoclax. Obatoclax and lapatinib treatment or obatoclax and CDK inhibitor treatment or lapatinib and CDK inhibitor treatment radiosensitized breast cancer cells. Lapatinib and obatoclax interacted to suppress mammary tumor growth in vivo. Collectively our data demonstrate that manipulation of MCL-1 protein expression by CDK inhibition or inhibition of MCL-1 sequestering function by Obatoclax renders breast cancer cells more susceptible to BAX/BAK-dependent mitochondrial dysfunction and tumor cell death.

AB - The present studies have examined approaches to suppress MCL-1 function in breast cancer cells, as a means to promote tumor cell death. Treatment of breast cancer cells with CDK inhibitors (flavopiridol; roscovitine) enhanced the lethality of the ERBB1 inhibitor lapatinib in a synergistic fashion. CDK inhibitors interacted with lapatinib to reduce MCL-1 expression and overexpression of MCL-1 or knock down of BAX and BAK suppressed drug combination lethality. Lapatinib-mediated inhibition of ERK1/2 and to a lesser extent AKT facilitated CDK inhibitor-induced suppression of MCL-1 levels. Treatment of cells with the BH3 domain/MCL-1 inhibitor obatoclax enhanced the lethality of lapatinib in a synergistic fashion. Knock out of MCL-1 and BCL-XL enhanced lapatinib toxicity to a similar extent as obatoclax and suppressed the ability of obatoclax to promote lapatinib lethality. Pre-treatment of cells with lapatinib or with obatoclax enhanced basal levels of BAX and BAK activity and further enhanced drug combination toxicity. In vivo tumor growth data in xenograft and syngeneic model systems confirmed our in vitro findings. Treatment of cells with CDK inhibitors enhanced the lethality of obatoclax in a synergistic fashion. Overexpression of MCL-1 or knock down of BAX and BAK suppressed the toxic interaction between CDK inhibitors and obatoclax. Obatoclax and lapatinib treatment or obatoclax and CDK inhibitor treatment or lapatinib and CDK inhibitor treatment radiosensitized breast cancer cells. Lapatinib and obatoclax interacted to suppress mammary tumor growth in vivo. Collectively our data demonstrate that manipulation of MCL-1 protein expression by CDK inhibition or inhibition of MCL-1 sequestering function by Obatoclax renders breast cancer cells more susceptible to BAX/BAK-dependent mitochondrial dysfunction and tumor cell death.

KW - BAK

KW - BCL-2 inhibitor

KW - CDK inhibitor

KW - Flavopiridol

KW - Lapatinib

KW - MCL-1

KW - Obatoclax

KW - Roscovitine

KW - RTK inhibitor

UR - http://www.scopus.com/inward/record.url?scp=78549257149&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78549257149&partnerID=8YFLogxK

U2 - 10.4161/cbt.10.9.13273

DO - 10.4161/cbt.10.9.13273

M3 - Article

C2 - 20855960

AN - SCOPUS:78549257149

VL - 10

SP - 903

EP - 917

JO - Cancer Biology and Therapy

JF - Cancer Biology and Therapy

SN - 1538-4047

IS - 9

ER -